Book contents
- The Neuropsychology of Dementia
- The Neuropsychology of Dementia
- Copyright page
- Contents
- Preface
- Acknowledgements
- Section 1 Essential Background Knowledge
- Section 2 Diagnosing Different Types of Dementia
- Section 3 Intervention
- Section 4 Recent Developments/Contemporary Issues
- Chapter 13 Biomarkers and Imaging
- Chapter 14 Dementia and Mental Capacity
- Index
- References
Chapter 13 - Biomarkers and Imaging
from Section 4 - Recent Developments/Contemporary Issues
Published online by Cambridge University Press: 25 October 2024
Book contents
- The Neuropsychology of Dementia
- The Neuropsychology of Dementia
- Copyright page
- Contents
- Preface
- Acknowledgements
- Section 1 Essential Background Knowledge
- Section 2 Diagnosing Different Types of Dementia
- Section 3 Intervention
- Section 4 Recent Developments/Contemporary Issues
- Chapter 13 Biomarkers and Imaging
- Chapter 14 Dementia and Mental Capacity
- Index
- References
Summary
This chapter reviews the use of biomarkers, including brain imaging. These techniques have revolutionised dementia research, although their availability for regular clinical practice is still developing. The chapter begins with a review of structural imaging techniques such as CT and MRI, and discusses the use of the dementia evolution scale. Functional techniques such as fMRI, SPECT, and PET are reviewed, including amyloid PET scans, which can identify the presence of beta amyloid protein and its distribution throughout the brain.
- Type
- Chapter
- Information
- The Neuropsychology of DementiaA Clinician's Manual, pp. 159 - 164Publisher: Cambridge University PressPrint publication year: 2024
References
Albert, M. S., DeKosky, S. T., Dickson, D., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 7(3), 270–9.CrossRefGoogle ScholarPubMed
Anchisi, D., Borroni, B., Franceschi, M., et al. (2005). Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology, 62(11), 1728–33.CrossRefGoogle ScholarPubMed
Beynon, R., Sterne, J. A., Wilcock, G., et al. (2012). Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurology, 12(1), 1–10.CrossRefGoogle Scholar
Biomarkers Working Definitions Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69(3), 89–96.CrossRefGoogle Scholar
Bloudek, L. M., Spackman, D. E., Blankenburg, M., & Sullivan, S. D. (2011). Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. Journal of Alzheimer’s Disease, 26(4), 627–45.Google ScholarPubMed
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I., et al. (2019). Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. JAMA Neurology, 76(8), 915–24.CrossRefGoogle ScholarPubMed
Harper, L., Barkhof, F., Scheltens, P., Schott, J. M., & Fox, N. C. (2014). An algorithmic approach to structural imaging in dementia. Journal of Neurology, Neurosurgery & Psychiatry, 85(6), 692–8.CrossRefGoogle ScholarPubMed
Jack Jr, C. R., Bennett, D. A., Blennow, K., et al. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–62.Google Scholar
Khoury, R., & Ghossoub, E. (2019). Diagnostic biomarkers of Alzheimer’s disease: A state-of-the-art review. Biomarkers in Neuropsychiatry, 1, 100005.CrossRefGoogle Scholar
Koedam, E. L., Lehmann, M., van der Flier, W. M., et al. (2011). Visual assessment of posterior atrophy development of a MRI rating scale. European Radiology, 21, 2618–25.CrossRefGoogle ScholarPubMed
Lewczuk, P., Riederer, P., O’Bryant, S. E., et al. (2018). Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. The World Journal of Biological Psychiatry, 19(4), 244–328.CrossRefGoogle ScholarPubMed
McKeith, I. G., Boeve, B. F., Dickson, D. W., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 89(1), 88–100.CrossRefGoogle ScholarPubMed
O’Brien, J. T., Firbank, M. J., Davison, C., et al. (2014). 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. Journal of Nuclear Medicine, 55(12), 1959–65.CrossRefGoogle ScholarPubMed
Orleans-Foli, S., Isaacs, S., & Cook, L. (2018). London Dementia Clinical Network Neuroimaging for dementia diagnosis: Guidance from the London Dementia Clinical Network. www.england.nhs.uk/london/wp-content/uploads/sites/8/2019/09/Neuroimaging-for-dementia-diagnosis-London-Dementia-Clinical-Network.pdf.Google Scholar
Palmqvist, S., Mattsson, N., Hansson, O., & Alzheimer’s Disease Neuroimaging Initiative. (2016). Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain, 139(4), 1226–36.CrossRefGoogle ScholarPubMed
Pasquier, F., Leys, D., Weerts, J. G., Mounier-Vehier, F., Barkhof, F., & Scheltens, P. (1996). Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. European Neurology, 36(5), 268–72.CrossRefGoogle ScholarPubMed
Pemberton, H. G., Zaki, L. A., Goodkin, O., et al. (2021). Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis – a systematic review. Neuroradiology, 63(11), 1773–89.Google ScholarPubMed
Poser, C. M., & Brinar, V. V. (2001). Diagnostic criteria for multiple sclerosis. Clinical Neurology and Neurosurgery, 103(1), 1–11.CrossRefGoogle ScholarPubMed
Radiology Assistant. https://radiologyassistant.nl/neuroradiology/dementia/role-of-mri.Google Scholar
Radiopedia (2023). SPECT vs PET. https://radiopaedia.org/articles/spect-vs-pet?lang=gb.Google Scholar
Scheltens, P., Leys, D., Barkhof, F., et al. (1992). Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer’s disease and normal ageing: Diagnostic value and neuropsychological correlates. Journal of Neurology, Neurosurgery & Psychiatry, 55(10), 967–72.CrossRefGoogle ScholarPubMed
Smith, J. J., Sorensen, A. G., & Thrall, J. H. (2003). Biomarkers in imaging: Realizing radiology’s future. Radiology, 227(3), 633–8.CrossRefGoogle ScholarPubMed
Valotassiou, V., Sifakis, N., Paptriantafyllou, J., Angelidis, G., & Georgoulias, P. (2011). The clinical use of SPECT and PET molecular imaging in Alzheimer’s disease. In De La Monte, S. (Ed). The Clinical Spectrum of Alzheimer’s Disease. InTech Open.Google Scholar
Wahlund, L. O., Barkhof, F., Fazekas, F., et al. (2001). A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke, 32(6), 1318–22.CrossRefGoogle ScholarPubMed
Yeo, J. M., Lim, X., Khan, Z., & Pal, S. (2013). Systematic review of the diagnostic utility of SPECT imaging in dementia. European Archives of Psychiatry and Clinical Neuroscience, 263, 539–52.CrossRefGoogle ScholarPubMed